Study of 5-17-month-old children [2] .
RTS,S/AS01E Rabies

All subjects
Severe adverse events, per-subject analysis N = 447 Percent (95% CI) N = 447 Percent (95% CI) Any SAE 47 11 (8- and non-malaria serious adverse events and vaccine efficacy in the two trials separately for each sex" [1] . Many parents, the FDA, local regulatory authorities and IRBs, want children to benefit from a vaccine rather than a placebo where an appropriate choice for a control exists. Young children are at risk of rabies in East Africa, and the disease is fatal if acquired. Pre-exposure prophylaxis is not widespread in Kenya and Tanzania, but is of proven benefit [4] . The licensed human diploid-cell rabies vaccine (rabies vaccine BP, Sanofi-Pasteur) was therefore an appropriate control for RTS,S/AS01E vaccination of 5-17-month-old children.
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In EPI (extended programme of immunisation) schedules children are routinely vaccinated against hepatitis B, and it would not have been acceptable to withhold this vaccination in the control group [5] . RTS,S/AS02D includes the hepatitis B surface antigen. It raises an antibody response to this antigen in infants [6] , and so replaces the hepatitis B vaccine that would otherwise have been part of the EPI schedule. The design of both trials was approved by IRB and regulatory authority review.
Dr. Aaby and co-workers have described non-specific deleterious effects of inactivated vaccines in Sub-Saharan Africa [7] . In Dr. Aaby's work non-specific vaccine effects were particularly noted in girls rather than boys [8] . He therefore proposes we re-analyse our safety data separately by gender. In 5-17-month-old children the SAE rates by vaccination allocation appeared consistent by girls and boys (Table 1 ). In the EPI schedule trial, the difference in SAE rates by vaccination was more pronounced for boys than girls ( Table 2) . The difference in pneumonia SAEs was also more pronounced for boys.
Efficacy against clinical malaria was 53% (95%CI 28-69) in all 5-17-month-old children [2] , compared with 63% (95% CI 29-81) in boys and 41% (95% CI −3 to 67) in girls. Efficacy against first infection was 65% (95%CI, 21-85) in the EPI study [3] , compared with 52% (95%CI −40 to 84) in boys and 75% (95%CI 6-93) in girls.
Our phase II studies were not designed to examine inpatient morbidity in detail. Phase III studies to clarify these findings are underway. There seems little evidence of a non-specific effect by Dr. Aaby's proposed analysis, and control vaccinations will be used in accordance with regulatory authority and IRB advice.
